PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population (Q43697155)

26 November 2017

title

PIK3CA mutations in KRAS and BRAF wild type colorectal cancer patients. A study of Spanish population (English)

1 reference

26 November 2017

1 reference

3

1 reference

26 November 2017

author name string

Marta Herreros-Villanueva

1

1 reference

26 November 2017

Noemí Gomez-Manero

2

1 reference

26 November 2017

Carlos García-Girón

4

1 reference

26 November 2017

Maria Jesús Coma del Corral

5

1 reference

26 November 2017

language of work or name

1 reference

23 June 2010

1 reference

Molecular Biology Reports

26 November 2017

published in

1 reference

26 November 2017

volume

38

1 reference

26 November 2017

issue

2

1 reference

26 November 2017

page(s)

1347-1351

1 reference

26 November 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

The molecular therapy of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

First-line treatment strategies for elderly patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Targeting RAS signalling pathways in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

RAS oncogenes: the first 30 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Hyperactive Ras in developmental disorders and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Mutation of the PIK3CA oncogene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Functional analysis of PIK3CA gene mutations in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Mode of action and application of Scorpion primers to mutation detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Detection of PCR products using self-probing amplicons and fluorescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Multiplexed assays for detection of mutations in PIK3CA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

The prevalence of PIK3CA mutations in gastric and colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0236-6

Oncogenic mutations of PIK3CA in human cancers

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20571907

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20571907

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11033-010-0236-6

1 reference

26 November 2017

1 reference